If you only glanced at Cegedim’s latest half year figures, the story might look upbeat. Revenue was slightly higher, net income excluding exceptional items improved, and the net margin moved from 0.4% in H1 2025 to 1.7% in H1 2026. For Cegedim shareholders, the loss from the start of the year was 30.1%, including dividends. If you were weighing an investment back on 1 January 2026, what clues were already visible that this outcome was on the table?
A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
Cegedim has already moved. See which of 193 high quality undervalued stocks still trade below our estimates.
The Two Stories Cegedim Investors Were Weighing Up
The shares cost €13.55 at the start of the period, and anyone looking at Cegedim then had to choose between two very different stories that both sounded reasonable.
On the optimistic side, the bullish Narrative saw Fair Value at €17. It leaned on migration of operations to Morocco and tighter cost control to lift long run margins, supported by cloud and AI investments aimed at higher recurring SaaS income.
The cautious view put Fair Value at €11. That bear case focused on heavy legacy IT dependence and underperforming core pharmacist software divisions, with rising compliance demands seen as a key risk to future profitability.
What The Results Changed For Cegedim
The clearest fresh evidence for Cegedim came in the H1 2026 report. Total revenue was €322.5m in H1 2025 and €324.8m in H1 2026. Net income excluding exceptional items moved from €1.2m to €5.5m and the net margin shifted from 0.4% to 1.7%. That pattern supported the optimistic cost control story, but it did not remove the cautious case on legacy risks.
The key assumption here was margin improvement. When you assess another stock built on a similar promise, track whether net income and net margin move in the same direction as claimed in the thesis once fresh results arrive.
What You Are Paying For In Cegedim After A 30% Fall
Cegedim now trades at €9.68, after a 30.1% loss from the start of the year. The analyst consensus Narrative on Simply Wall St sees Fair Value above that level, based on a recovery story that leans heavily on AI tools and electronic invoicing.
For this drop to look like an opportunity rather than a warning, a buyer today would need to believe that AI driven efficiency and e-invoicing can outweigh ongoing Healthcare Professionals losses and heavier capex.
"The ramp up of AI tools across Cegedim’s developers, BPO teams, payroll, insurance case handling and customer support, together with AI features such as the Ed assistant in Maiia Médecin, Voca AI and Claude Bernard AI, can support future operating efficiency and revenue per user, which would feed into higher earnings."
The price and this Narrative do not agree. → Uncover what this Narrative says Cegedim is actually worth
Looking One Step Beyond Cegedim
Cegedim leans heavily on software and data to streamline healthcare workflows. You can look one step away and ask where similar tools already run at scale.
Another large healthcare group earns its keep by running benefit plans and pharmacy services. It also sells software, analytics and outsourced operations to hospitals and insurers.
The shared need is clear. Both Cegedim and this peer rely on technology that keeps claims processing, care management and clinical documentation efficient.
At that peer, AI now targets claims, call centers and back office tasks. If that push works, it could quietly reset cost expectations across healthcare IT.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 19% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com